Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Cash from Financing Activities of -$412.3 million for Q2 2026, down 33162.87% year-over-year from N/an in Q2 2025, and down 820.06% quarter-over-quarter from $57.3 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$412.3 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 33162.87% year-over-year to -$412.3 million; the TTM figure through Jun 2026 stood at $317.4 million (down 30.31% YoY), while the FY2025 annual figure was $675.8 million, up 41.37% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$412.3 million, down from $57.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $591.2 million in Q4 2025, with the low at -$412.3 million in Q2 2026.
- The 5-year median for Cash from Financing Activities is $2.4 million (2024), against an average of $77.1 million.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 11713.83% in 2023, then plunged 33162.87% in 2026.
- Ionis Pharmaceuticals' Cash from Financing Activities stood at -$51.0 million in 2022, then surged by 179.82% to $40.7 million in 2023, then slumped by 208.33% to -$44.1 million in 2024, then jumped by 1440.05% to $591.2 million in 2025, then plunged by 169.74% to -$412.3 million in 2026.
- Business Quant data shows IONS's Cash from Financing Activities at -$412.3 million in Q2 2026, $57.3 million in Q1 2026, and $591.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | -412.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -412.29 Mn |
| Jun 30, 2026 | -412.29 Mn |
| Mar 31, 2026 | 57.26 Mn |
| Mar 31, 2026 | 57.26 Mn |
| Dec 31, 2025 | 591.18 Mn |
| Dec 31, 2025 | 591.18 Mn |
| Sep 30, 2025 | 81.22 Mn |
| Sep 30, 2025 | 81.22 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | -44.12 Mn |
| Dec 31, 2024 | -44.12 Mn |
| Sep 30, 2024 | 496.05 Mn |
| Sep 30, 2024 | 496.05 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 23.57 Mn |
| Mar 31, 2024 | 23.57 Mn |